Adjuvant intravesicular chemotherapy for superficial bladder carcinoma
https://doi.org/10.17650/1726-9776-2007-3-3-43-45
Abstract
The paper presents the results of using Vero-Mitomycin in patients with superficial bladder carcinoma (SBC). The study included 23 SBC patients over 18 years of age, with invasion levels of pTa, pT1, and differentiation grades of G1—2, ECOG 0 or 1, who were treated at the Department of Oncourology, P.A. Herzen Moscow Research Oncological Institute. The patients were given 6 intravesicular instillations of Vero-Mitomycin in a single dose of 40 mg. During a follow-up, a recurrence developed in 9 (39.1%) patients, a tumorous process progressed in none patient. There were recurrences at 12—16 months. The acute cystitis syndrome was revealed in 2 patients (after 4 and 6 instillations of the drug). Hematological toxicity was not observed. Thus, Vero-Mitomycin is one of the drugs of choice for the first-line intravesicular chemotherapy in patients with low and moderate risk SBC. Intravesicular chemotherapy with Vero-Mitomycin is an effective and low-toxic preventive method against recurrent SBC.
About the Authors
I. G. Rusakov
P.A. Herzen Moscow Research Oncological Institute
Russian Federation
Russian Federation
A. A. Bystrov
P.A. Herzen Moscow Research Oncological Institute
Russian Federation
Russian Federation
A. A. Teplov
P.A. Herzen Moscow Research Oncological Institute
Russian Federation
Russian Federation
D. V. Perepechin
P.A. Herzen Moscow Research Oncological Institute
Russian Federation
Russian Federation
References
1. Soloway M.S., Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer. 1980;46(5):1158—63.
2. Hirao Y., Okajima E., Ohara S. et al. Prophylactic treatment for superficial bladder cancer following transurethral resection. Cancer Chemother Pharmacol 1987;20 (Suppl):S85—90.
3. Elmer A., Bermes U., Drath L. et al. Sepsis and multiple organ failure after BCG-instillation for bladder cancer. Internist (Berl) 2004;45(8):935—9.
4. Carballido J., Molto L.M., Olivier D.P. et al. Analysis of the effect of intravesical treatment with interfero-a-2b on clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors. Anti-Cancer Drugs 1992; 3(Suppl1): 9—12.
5. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., Вердана; 2001.
6. Heijden A.G. van der, Witjes J.A. Future strategies in the diagnosis, staging and treatment of bladder cancer. Curr Opin Urol 2003;13(5):389—95.
7. Shelley M.D., Court J.B., Kynaston H. et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003;(3):CD003231.
8. Soulie M., Straub M., Game X. et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol 2002;167(3):1325—8.
Review
For citations:
Rusakov I.G., Bystrov A.A., Teplov A.A., Perepechin D.V. Adjuvant intravesicular chemotherapy for superficial bladder carcinoma. Cancer Urology. 2007;3(3):43-45. (In Russ.) https://doi.org/10.17650/1726-9776-2007-3-3-43-45
Views:
268
Email this article 